IP Library Granted Patent US 12699095
Granted Patent B2
US 12699095 · App. 16/736,325 · Granted Aug 4, 2026

Cancer diagnosis using Ki-67

Inventors: Jean Marie Bruey (Encinitas, CA); Maher Albitar (Coto De Caza, CA)
Assignee: Quest Diagnostics Investments LLC
G01N33/575G01N33/57505G01N2800/52G01N2800/56
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12699095
App. No.
16/736,325
Granted
Aug 4, 2026
Kind
B2
Abstract

The present invention provides methods and compositions for detection, diagnosis, prognosis, monitoring treatment and monitoring progression of cancer by detecting the level of Ki-67 protein in an individual.

Claims (16)

1 . A method comprising:

(a) obtaining a plasma sample from a subject suspected of having lymphoma;

(b) contacting the plasma sample with an agent that binds to a Ki-67 protein that is detectable in the plasma sample, wherein the plasma sample contains less than about 1% (w/w) whole cellular material; and

(c) detecting a level of Ki-67 protein in the plasma sample by performing an immunoassay, wherein the level of Ki-67 protein is above about 1500 U/mL.

2 . The method of claim 1 , wherein (a) comprises centrifuging the plasma sample.

3 . The method of claim 1 , wherein the agent is immobilized on a support.

4 . The method of claim 3 , wherein the support is a microwell, bead, or microarray.

5 . The method of claim 3 , wherein the support is nitrocellulose, glass, polyacrylamides, gabbros, or magnetite.

6 . The method of claim 3 , wherein the support is spherical, cylindrical, or flat.

7 . The method of claim 1 , wherein the agent is an anti-Ki-67 antibody.

8 . The method of claim 7 , wherein the anti-Ki-67 antibody is labeled with a detectable label.

9 . The method of claim 8 , wherein the detectable label is selected from the group consisting of a radioisotope, enzyme, enzyme substrate, luminescent substance, biotinyl group, and predetermined polypeptide epitope recognized by a secondary reporter.

10 . The method of claim 1 , wherein the Ki-67 protein comprises the amino acid sequence of SEQ ID NO: 1.

11 . The method of claim 1 , wherein the immunoassay is selected from a radioimmunoassay, immunoprecipitation, Western blot, enzyme-linked immunosorbent assay (ELISA), electrochemiluminescence assay, or 2-site or sandwich immunoassay.

12 . The method of claim 1 , wherein the lymphoma is non-Hodgkin's lymphoma (NHL) or Burkitt's lymphoma.

13 . The method of claim 1 , further comprising measuring a level of β2-microglobulin in the plasma sample.